BIOGRAPHICAL SKETCH

Academic & Professional Background

• B.S. 1971 - Massachusetts Institute of Technology, Cambridge
• Research Biologist 1972 - Boston University School of Medicine, Massachusetts
• M.D. 1976 - Boston University, Massachusetts
• Internship (Medicine) 1977 - Michael Reese Hospital & Medical Center, Chicago, Illinois
• Assistant Resident (Medicine) 1978 - Michael Reese Hospital & Medical Center, Chicago, Illinois
• Senior Assistant Resident (Medicine) 1979 - Michael Reese Hospital & Medical Center, Chicago, Illinois
• Fellow (Nephrology) 1981 - University of Chicago Hospitals, Illinois

Current Research Interests

• Diabetic Nephropathy
• Anemia in Kidney Disease

Selected Publications

Singh R, Song RH, Alavi N, Pegoraro AA, Singh AK, Leehey DJ. High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta 1. Exp Nephrol 0:249-57, 2001.

Leehey DJ, Singh AK, Alavi N, Singh R. Role od angiotensin II in diabetic nephropathy. Kidney International 58(77)S93-98, 2000.

Mirza BI, Sahani M, Leehey DJ, Patel SB, Yang VL, Ing TS. Saline-induced dilutional acidosis in a maintenance hemodialysis patient. Int J Artif Organs 22:676-678, 1999.

Song RH, Singh AK, Leehey DJ. Decreased glomerular proteinase activity in the streptozotocin diabetic rat. Am J Nephrol 19:441-446, 1999.

Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48:2066-2073, 1999.

Chow MT, Lin HJ, Mira EA, Singh E, Lee F, Leehey DJ, Ing TS. Hemodialysis-induced hypophosphatemia in normophosphatemic patient dialyzed for ethylene glycol poisoning: Treatment with phosphorus-enriched hemodialysis. Artificial Organs 22:905-913, 1998.

Emilife-Obi C, Chow MT, Qamar-Rohail H, Leehey DJ, Gandhi VC, Ing TS. Use of a phosphorus-enriched hemodialysate to prevent hypophosphatemia in a patient with renal failure-related pericarditis. Clin Nephrol 50:131-133, 1998.

Leehey DJ, Song RT, Alavi N, Singh AK. Decreased degradative enzymes in mesongial cells cultured in high glucose media. Diabetes 44:929-935, 1995.

Singh AK, Song RH, Frankfater AF, Leehey DJ. Physiological and biochemical response of glomerular epithelial cells to exogenous epidermal growth factor. Esp Nephrol 3:355-361, 1995.

Leehey DJ. Hemodialysis in the diabetic patient with end-stage renal disease. Renal Failure 16:547-553, 1994.

Leehey DJ. Dissociation between in vivo pressor sensitivity and in vitro contractile reactivity to angiotensin II in rats with experiemental cirrhosis. Clin Sci 84:525-529, 1993.

Reid RW, Deakin A, Leehey DJ. Measurement of naloxone in plasma using high performance lighid chromatography and electrochemical detection. J Chromatogr 614:117-122, 1993.

Leehey DJ, Braun BI, Tholl DA, Chung LS, Gross CA, Roback JA, Lentino JR. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy? J Am Soc Nephrol 4:81-90, 1993.

Kar PM, Kellner K, Ing TS, Leehey DJ. Combined high efficiency hemodialysis and charcoal hemoperfusion in severe N-acetylprocainamide intoxication. Am J Kidney Dis 20:403-406, 1992.

Leehey DJ, Gollopudi P, Deakin A, Reid RW. Naloxone increases sodium and water excretion after water loading in patients with cirrhosis and ascites. J Lab Clin Med 118:484-491, 1991.

Projects Completed or Active (Selected)

• Hyponatremia in Spinal Cord Injured Patients
• Individualized Dosing of Aminoglycosides
• Role of Endogenous Opioids in Non-Osmotic Vasopressin Release
• Opioids and Water Excretion in Cirrhosis
• Effect of Naloxone on Sodium and Water Excretion in Congestive Heart Failure
• Effect of Naloxone on Renal Functions in Liver Cirrhosis
• Matrix Degradation in Diabetic Glomerulopathy
• Effect of the Angiotensin II Antagonists on Mesogial Matrix Degradation in Diabetes

Research Funding Sources

• American Diabetes Association
• Chicago Heart Association
• Merck Medical School Grants Committee
• National Institute of Health
• VA Health Services Research & Development
• VA Merit Review

Research Methods Employed

• Radioimmunoassay
• Ischemic/Toxic Renal Injury Models
• Experimental Liver Cirrhosis Model
• Renal Clearance Methods
• High Performance Liquid Chromotography (HPLC)
• Renal Cell Culture
• Molecular Methods (Northern & Western Blots, etc.)
• Experimental Diabetes
• Zymography
• Proteinase Assays

Honors

• 2000 - Associate Editor, Hypertension, Dialysis, and Clinical Nephrology (HDCN)
• 2000 - Invited Speaker, Fourth Hyonam Kidney Laboratory International Symposium on Diabetic Kidney disease Research, Seoul, Korea
• 1999-2000 - Reviewer, VA Merit Review
• 1998 - Invited Speaker, American Diabetes Association Public Conference, Chicago, Illinois
• 1997-present - Invited Participant, Iron Managment Speakers Bureau
• 1997 - Invited Faculty Member, Practical Computing for Nephrologists, San Antonio, Texas
• 1996-present - Invited Participant, Schein Speakers Bureau
• 1993 - Invited Participant, International Symposium on Pathogenesis and Treatment of Diabetic Nephropathy
• 1988 - Member, Central Society for Clinical Research
• 1987 - Invited Participant, Second International Vasopressin Conference
• 1987 - Invited Participant, Symposia on "Hypertension: The Heart and Kidney" - Sponsored by Marion Laboratories
• 1986 - Fellow, American College of Physicians